<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7136311/results/search/disease/results.xml">
  <result pre="of pregnancy: systematic review and network meta-analysis WuYuchao1LiuJinfeng1FengYali1FuShan1JiFanpu2GeLong34YaoNaijuan1LuoXufei34ZhaoYingren1ChenYaolongsinograde@163.com34YangYuanxayanyuan@126.com1http://orcid.org/0000-0003-4823-9507ChenTianyanchentianyan@126.com1[1], grid.452438.cDepartment of" exact="Infection" post="Disease and Hepatopathy, First Affiliated Hospital of Xi’an Jiaotong"/>
  <result pre="pregnancy: systematic review and network meta-analysis WuYuchao1LiuJinfeng1FengYali1FuShan1JiFanpu2GeLong34YaoNaijuan1LuoXufei34ZhaoYingren1ChenYaolongsinograde@163.com34YangYuanxayanyuan@126.com1http://orcid.org/0000-0003-4823-9507ChenTianyanchentianyan@126.com1[1], grid.452438.cDepartment of Infection" exact="Disease" post="and Hepatopathy, First Affiliated Hospital of Xi’an Jiaotong University,"/>
  <result pre="systematic review and network meta-analysis WuYuchao1LiuJinfeng1FengYali1FuShan1JiFanpu2GeLong34YaoNaijuan1LuoXufei34ZhaoYingren1ChenYaolongsinograde@163.com34YangYuanxayanyuan@126.com1http://orcid.org/0000-0003-4823-9507ChenTianyanchentianyan@126.com1[1], grid.452438.cDepartment of Infection Disease" exact="and Hepatopathy," post="First Affiliated Hospital of Xi’an Jiaotong University, [2], grid.452672.0Department"/>
  <result pre="First Affiliated Hospital of Xi’an Jiaotong University, [2], grid.452672.0Department of" exact="Infection" post="Disease and Hepatopathy, Second Affiliated Hospital of Xi’an Jiaotong"/>
  <result pre="Affiliated Hospital of Xi’an Jiaotong University, [2], grid.452672.0Department of Infection" exact="Disease" post="and Hepatopathy, Second Affiliated Hospital of Xi’an Jiaotong University,"/>
  <result pre="Hospital of Xi’an Jiaotong University, [2], grid.452672.0Department of Infection Disease" exact="and Hepatopathy," post="Second Affiliated Hospital of Xi’an Jiaotong University, [3], grid.32566.340000"/>
  <result pre="Results 3 Randomized and 32 nonrandomized studies enrolling 6738 pregnant" exact="female" post="were included. Using network analysis, any antiviral agent interrupted"/>
  <result pre="preventing MTCT. Compared with the initiation during the third trimester," exact="lower" post="rate of MTCT was revealed when antiviral therapy was"/>
  <result pre="contains supplementary material, which is available to authorized users. Keywords" exact="Hepatitis" post="B Mother-to-child transmission Pregnancy Antiviral treatment Network meta-analysis Lamivudine"/>
  <result pre="is available to authorized users. Keywords Hepatitis B Mother-to-child transmission" exact="Pregnancy" post="Antiviral treatment Network meta-analysis Lamivudine Telbivudine Tenofovir Efficacy Safety"/>
  <result pre="Project S2018-YF-ZDSF-0240ChenTianyan Funding National Science and Technology Projects on Major" exact="Infectious" post="Diseases2017ZX10202202-002-006ZhaoYingren Introduction Perinatal or intrauterine transmission is the major"/>
  <result pre="its area of high endemicity [1]. Since the last decades," exact="hepatitis" post="B vaccination and immunoglobulin administration provided at birth have"/>
  <result pre="of HBV [2]. However, 50 Mio. new cases of HBV" exact="infection" post="are still diagnosed annually due to mother-to-child transmission, MTCT"/>
  <result pre="safe in reducing the risk of HBV MTCT if pregnant" exact="female" post="were carrying high viral load of HBV [6]. Emerging"/>
  <result pre="risk of HBV MTCT if pregnant female were carrying high" exact="viral" post="load of HBV [6]. Emerging data suggest the application"/>
  <result pre="still reported even if their mothers obtained a treatment in" exact="late pregnancy" post="[12, 13]. The well efficacy and safety in preventing"/>
  <result pre="of head-to-head comparisons [15] by indirect means. Thus, for our" exact="primary" post="objective to identify the effective timing of starting AVT,"/>
  <result pre="a distinction of the period between the early-middle pregnancy and" exact="late pregnancy" post="on agent use in preventing perinatal transmission. Our secondary"/>
  <result pre="late pregnancy on agent use in preventing perinatal transmission. Our" exact="secondary" post="objectives were set to determine safety outcomes among different"/>
  <result pre="3 RCTs and 32 nonrandomized studies, were selected. 6738 pregnant" exact="female" post="were enrolled in our analysis (Fig. 1). 28 in"/>
  <result pre="the studies (74%, 26/35) were conducted in China among pregnant" exact="female" post="that started AVT across different trimesters because of a"/>
  <result pre="that started AVT across different trimesters because of a high" exact="viral" post="load of HBV DNA. All infants received HBV vaccination"/>
  <result pre="RR 0.06; 95% CI 0.03 to 0.10, Fig. 2a) and" exact="late pregnancy" post="(21 non-RCTs: RR 0.19; 95% CI 0.11 to 0.32,"/>
  <result pre="for infants at 6–12 months after delivery. AVT used prior" exact="late pregnancy" post="although didn’t have significant difference but tended to have"/>
  <result pre="HBV vertical transmission, as compared with the treatment administrated in" exact="late pregnancy" post="(RR, 0.25; 95% CI 0.03 to 2.32, Fig. 2c)."/>
  <result pre="to reduce the risk by 3.5% over the administration in" exact="late pregnancy." post="This means that the probability of AVT before the"/>
  <result pre="efficacy in interrupting MTCT separately when comparing with untreated pregnant" exact="female" post="(Fig. S2a, b). Network meta-analysis Previous studies have indicated"/>
  <result pre="S6 and 5. As compared with the control group, pregnant" exact="female" post="that received AVT either prior third trimester (32 non-RCTs:"/>
  <result pre="early-middle pregnancy obtained superior efficacy to that intervention starting in" exact="late pregnancy" post="(32 non-RCTs: RR 0.033; 95% CI 0.0033 to 0.16,"/>
  <result pre="pregnancy (32 non-RCTs: RR 0.0015; 95% CI 3.7E−05 to − 0.03) and" exact="late pregnancy" post="(32 non-RCTs: RR 0.10; 95% CI 0.034 to 0.20)"/>
  <result pre="studies enrolling HBeAg positive mothers. Among the HBeAg positive pregnant" exact="female" post="received AVT treatment, initiation in middle pregnancy indicated an"/>
  <result pre="indicated an improved effect on reducing MTCT than initiation in" exact="late pregnancy" post="(RR 2.7E−18, 95% CI 6.0E−55, 0.0081, Fig. S9). Efficacy"/>
  <result pre="S10. Comparing with the untreated group, intervening in earlier and" exact="late pregnancy" post="both showed the significance of HBV DNA suppression, HBeAg"/>
  <result pre="seroconvension and ALT normalization. Comparing with the AVT initiated in" exact="late pregnancy," post="starting treatment in early-middle pregnancy had similar significant efficacy"/>
  <result pre="non-RCTs: RR, 1.2; 95% CI 1.1 to 1.3) than in" exact="late pregnancy." post="Safety for infant outcomes: network meta-analysis for non-RCTs When"/>
  <result pre="not show clear difference from others on the incidence of" exact="congenital" post="malformation rate, prematurity rate, Apgar scores &amp;lt; 8, fetal death, and"/>
  <result pre="the incidence of congenital malformation rate, prematurity rate, Apgar scores &amp;lt; 8," exact="fetal death," post="and low birth weight (Fig. S11). Safety for maternal"/>
  <result pre="indicated no difference from others according to the incidence of" exact="postpartum" post="hemorrhage, cesarean section, and elevated creatine kinase, gestational hypertension,"/>
  <result pre="incidence of postpartum hemorrhage, cesarean section, and elevated creatine kinase," exact="gestational" post="hypertension, membrane prerupture, oligohydramnios and polyhydramnios (Fig. S12). Quality"/>
  <result pre="cesarean section, and elevated creatine kinase, gestational hypertension, membrane prerupture," exact="oligohydramnios" post="and polyhydramnios (Fig. S12). Quality of evidence The quality"/>
  <result pre="and elevated creatine kinase, gestational hypertension, membrane prerupture, oligohydramnios and" exact="polyhydramnios" post="(Fig. S12). Quality of evidence The quality of the"/>
  <result pre="of RCTs and nRCTs studies for the prevention of HBV" exact="viral" post="MTCT, a comprehensive literature search was conducted with no"/>
  <result pre="study has published that LDT administrated throughout early, middle, or" exact="late pregnancy" post="is safe and effective to interrupt mother-to-infant transmission [39]."/>
  <result pre="administration of antiviral agents in early-middle pregnancy was associated with" exact="lower" post="MTCT of HBV than the use in late pregnancy."/>
  <result pre="associated with lower MTCT of HBV than the use in" exact="late pregnancy." post="LDT and TDF had a trend of prior use"/>
  <result pre="treatment provided in the third trimester and control group. High" exact="viral" post="load is independently associated with the high risk of"/>
  <result pre="to control mothers’ liver function and decrease the risk of" exact="viral" post="breakthrough during pregnancy. Current clinical guidelines reveal a range"/>
  <result pre="lack of researches. In addition, among the HBeAg positive pregnant" exact="female" post="received AVT treatment, initiation in middle pregnancy indicated an"/>
  <result pre="indicated an improved effect on reducing MTCT than initiation in" exact="late pregnancy." post="Accordingly, antiviral therapy should be at least provided to"/>
  <result pre="at least provided to HBeAg positive pregnant mothers with high" exact="viral" post="loads (&amp;gt; 2 × 106 IU/mL). Several systematic reviews and meta-analysis have"/>
  <result pre="Brown et al. recommended the use of these agents in" exact="female" post="who are HBeAg positive and high level of HBV"/>
  <result pre="mainly coming from non-RCTs cannot comprehensively reflect antiviral efficacy and" exact="lower" post="down the grade evidence of observation in the real-world."/>
  <result pre="range in many studies. Third, the distributions of patients and" exact="disease" post="background exist with selective bias based on non-randomized studies."/>
  <result pre="the third trimester, for HBeAg positive pregnant mothers with high" exact="viral" post="loads (&amp;gt; 2 × 106 IU/mL). The limited safety data regarded to"/>
  <result pre="positive pregnant mothers with high viral loads (&amp;gt; 2 × 106 IU/mL). The" exact="limited" post="safety data regarded to maternal and infant outcomes demonstrated"/>
  <result pre="(S2018-YF-ZDSF-0240), and the National Science and Technology Projects on Major" exact="Infectious" post="Diseases (13th Five Year, China) (Project No. 2017ZX10202202-002-006). The"/>
  <result pre="and the National Science and Technology Projects on Major Infectious" exact="Diseases" post="(13th Five Year, China) (Project No. 2017ZX10202202-002-006). The programs"/>
  <result pre="conflict of interest. References References 1.SchweitzerAHornJMikolajczykRTKrauseGOttJJEstimations of worldwide prevalence of" exact="chronic hepatitis" post="B virus infection: a systematic review of data published"/>
  <result pre="of interest. References References 1.SchweitzerAHornJMikolajczykRTKrauseGOttJJEstimations of worldwide prevalence of chronic" exact="hepatitis" post="B virus infection: a systematic review of data published"/>
  <result pre="published between 1965 and 2013Lancet (Lond Engl)201538615461555 2.KaneMAGlobal status of" exact="hepatitis" post="B immunisationLancet (Lond Engl)1996348696 3.BuchananCTranTTManagement of chronic hepatitis B"/>
  <result pre="2.KaneMAGlobal status of hepatitis B immunisationLancet (Lond Engl)1996348696 3.BuchananCTranTTManagement of" exact="chronic hepatitis" post="B in pregnancyClin Liver Dis20101449550420638027 4.LokASLaiCLWuPCLeungEKLamTSSpontaneous hepatitis B e"/>
  <result pre="status of hepatitis B immunisationLancet (Lond Engl)1996348696 3.BuchananCTranTTManagement of chronic" exact="hepatitis" post="B in pregnancyClin Liver Dis20101449550420638027 4.LokASLaiCLWuPCLeungEKLamTSSpontaneous hepatitis B e"/>
  <result pre="3.BuchananCTranTTManagement of chronic hepatitis B in pregnancyClin Liver Dis20101449550420638027 4.LokASLaiCLWuPCLeungEKLamTSSpontaneous" exact="hepatitis" post="B e antigen to antibody seroconversion and reversion in"/>
  <result pre="antigen to antibody seroconversion and reversion in Chinese patients with" exact="chronic hepatitis" post="B virus infectionGastroenterology198792183918433569757 5.LivingstonSESimonettiJPBulkowLRet al.Clearance of hepatitis B e"/>
  <result pre="to antibody seroconversion and reversion in Chinese patients with chronic" exact="hepatitis" post="B virus infectionGastroenterology198792183918433569757 5.LivingstonSESimonettiJPBulkowLRet al.Clearance of hepatitis B e"/>
  <result pre="patients with chronic hepatitis B virus infectionGastroenterology198792183918433569757 5.LivingstonSESimonettiJPBulkowLRet al.Clearance of" exact="hepatitis" post="B e antigen in patients with chronic hepatitis B"/>
  <result pre="5.LivingstonSESimonettiJPBulkowLRet al.Clearance of hepatitis B e antigen in patients with" exact="chronic hepatitis" post="B and genotypes A, B, C, D, and FGastroenterology20071331452145717920063"/>
  <result pre="al.Clearance of hepatitis B e antigen in patients with chronic" exact="hepatitis" post="B and genotypes A, B, C, D, and FGastroenterology20071331452145717920063"/>
  <result pre="A, B, C, D, and FGastroenterology20071331452145717920063 6.BrownRSJrMcMahonBJLokASet al.Antiviral therapy in" exact="chronic hepatitis" post="B viral infection during pregnancy: a systematic review and"/>
  <result pre="B, C, D, and FGastroenterology20071331452145717920063 6.BrownRSJrMcMahonBJLokASet al.Antiviral therapy in chronic" exact="hepatitis" post="B viral infection during pregnancy: a systematic review and"/>
  <result pre="D, and FGastroenterology20071331452145717920063 6.BrownRSJrMcMahonBJLokASet al.Antiviral therapy in chronic hepatitis B" exact="viral infection" post="during pregnancy: a systematic review and meta-analysisHepatology20166331933326565396 7.XuWMCuiYTWangLet al.Lamivudine"/>
  <result pre="and FGastroenterology20071331452145717920063 6.BrownRSJrMcMahonBJLokASet al.Antiviral therapy in chronic hepatitis B viral" exact="infection" post="during pregnancy: a systematic review and meta-analysisHepatology20166331933326565396 7.XuWMCuiYTWangLet al.Lamivudine"/>
  <result pre="during pregnancy: a systematic review and meta-analysisHepatology20166331933326565396 7.XuWMCuiYTWangLet al.Lamivudine in" exact="late pregnancy" post="to prevent perinatal transmission of hepatitis B virus infection:"/>
  <result pre="7.XuWMCuiYTWangLet al.Lamivudine in late pregnancy to prevent perinatal transmission of" exact="hepatitis" post="B virus infection: a multicentre, randomized, double-blind, placebo-controlled studyJ"/>
  <result pre="hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled studyJ" exact="Viral" post="Hepat2009169410319175878 8.PanCQDuanZDaiEet al.Tenofovir to prevent hepatitis B transmission in"/>
  <result pre="randomized, double-blind, placebo-controlled studyJ Viral Hepat2009169410319175878 8.PanCQDuanZDaiEet al.Tenofovir to prevent" exact="hepatitis" post="B transmission in mothers with high viral loadN Engl"/>
  <result pre="al.Tenofovir to prevent hepatitis B transmission in mothers with high" exact="viral" post="loadN Engl J Med20163742324233410.1056/NEJMoa150866027305192 9.JourdainGNgo-Giang-HuongNTenofovir versus placebo to prevent"/>
  <result pre="J Med20163742324233410.1056/NEJMoa150866027305192 9.JourdainGNgo-Giang-HuongNTenofovir versus placebo to prevent perinatal transmission of" exact="hepatitis" post="BN Engl J Med201837891192329514030 10.ZhangHPanCQPangQTianRYanMLiuXTelbivudine or lamivudine use in"/>
  <result pre="hepatitis BN Engl J Med201837891192329514030 10.ZhangHPanCQPangQTianRYanMLiuXTelbivudine or lamivudine use in" exact="late pregnancy" post="safely reduces perinatal transmission of hepatitis B virus in"/>
  <result pre="lamivudine use in late pregnancy safely reduces perinatal transmission of" exact="hepatitis" post="B virus in real-life practiceHepatology201460246847625187919 11.PanCQYiWLiuMWanGHuYHZhouMFLamivudine therapy during the"/>
  <result pre="the second vs the third trimester for preventing transmission of" exact="chronic hepatitis" post="BJ Viral Hepat20172424625228025872 12.YiWLiMHXieYet al.Prospective cohort study on the"/>
  <result pre="second vs the third trimester for preventing transmission of chronic" exact="hepatitis" post="BJ Viral Hepat20172424625228025872 12.YiWLiMHXieYet al.Prospective cohort study on the"/>
  <result pre="the third trimester for preventing transmission of chronic hepatitis BJ" exact="Viral" post="Hepat20172424625228025872 12.YiWLiMHXieYet al.Prospective cohort study on the efficacy and"/>
  <result pre="of telbivudine used throughout pregnancy in blocking mother-to-child transmission of" exact="hepatitis" post="B virusJ Viral Hepat201724Suppl 1495629082650 13.LiuYWangMYaoSet al.Efficacy and safety"/>
  <result pre="throughout pregnancy in blocking mother-to-child transmission of hepatitis B virusJ" exact="Viral" post="Hepat201724Suppl 1495629082650 13.LiuYWangMYaoSet al.Efficacy and safety of telbivudine in"/>
  <result pre="of pregnancy with high viremia for interrupting perinatal transmission of" exact="hepatitis" post="B virusHepatol Res Off J Jpn Soc Hepatol201646E181E188 14.HeTBaiYCaiHet"/>
  <result pre="or telbivudine started in early pregnancy for mothers with active" exact="chronic hepatitis" post="BHepatol Int20181211812529344772 15.CiprianiAHigginsJPGeddesJRSalantiGConceptual and technical challenges in network meta-analysisAnn"/>
  <result pre="telbivudine started in early pregnancy for mothers with active chronic" exact="hepatitis" post="BHepatol Int20181211812529344772 15.CiprianiAHigginsJPGeddesJRSalantiGConceptual and technical challenges in network meta-analysisAnn"/>
  <result pre="challenges in network meta-analysisAnn Intern Med201315913013723856683 16.ThilakanathanCWarkGMaleyMet al.Mother-to-child transmission of" exact="hepatitis" post="B: examining viral cut-offs, maternal HBsAg serology and infant"/>
  <result pre="meta-analysisAnn Intern Med201315913013723856683 16.ThilakanathanCWarkGMaleyMet al.Mother-to-child transmission of hepatitis B: examining" exact="viral" post="cut-offs, maternal HBsAg serology and infant testingLiver Int Off"/>
  <result pre="Assoc Study Liver20183812121219 17.HuYXuCXuBet al.Safety and efficacy of telbivudine in" exact="late pregnancy" post="to prevent mother-to-child transmission of hepatitis B virus: a"/>
  <result pre="of telbivudine in late pregnancy to prevent mother-to-child transmission of" exact="hepatitis" post="B virus: a multicenter prospective cohort studyJ Viral Hepat20182542943729193547"/>
  <result pre="transmission of hepatitis B virus: a multicenter prospective cohort studyJ" exact="Viral" post="Hepat20182542943729193547 18.Samadi KochaksaraeiGCastilloEOsmanMet al.Clinical course of 161 untreated and"/>
  <result pre="Hepat20182542943729193547 18.Samadi KochaksaraeiGCastilloEOsmanMet al.Clinical course of 161 untreated and tenofovir-treated" exact="chronic hepatitis" post="B pregnant patients in a low hepatitis B virus"/>
  <result pre="18.Samadi KochaksaraeiGCastilloEOsmanMet al.Clinical course of 161 untreated and tenofovir-treated chronic" exact="hepatitis" post="B pregnant patients in a low hepatitis B virus"/>
  <result pre="and tenofovir-treated chronic hepatitis B pregnant patients in a low" exact="hepatitis" post="B virus endemic regionJ Viral Hepat201623152226192022 19.ChenHLLeeCNChangCHet al.Efficacy of"/>
  <result pre="pregnant patients in a low hepatitis B virus endemic regionJ" exact="Viral" post="Hepat201623152226192022 19.ChenHLLeeCNChangCHet al.Efficacy of maternal tenofovir disoproxil fumarate in"/>
  <result pre="of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of" exact="hepatitis" post="B virusHepatology20156237538625851052 20.GreenupAJTanPKNguyenVet al.Efficacy and safety of tenofovir disoproxil"/>
  <result pre="tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of" exact="hepatitis" post="B virusJ Hepatol20146150250724801414 21.AyresAYuenLJacksonKMet al.Short duration of lamivudine for"/>
  <result pre="Hepatol20146150250724801414 21.AyresAYuenLJacksonKMet al.Short duration of lamivudine for the prevention of" exact="hepatitis" post="B virus transmission in pregnancy: lack of potency and"/>
  <result pre="in pregnancy: lack of potency and selection of resistance mutationsJ" exact="Viral" post="Hepat20142180981724329944 22.ZhangLJWangLBlocking intrauterine infection by telbivudine in pregnant chronic"/>
  <result pre="potency and selection of resistance mutationsJ Viral Hepat20142180981724329944 22.ZhangLJWangLBlocking intrauterine" exact="infection" post="by telbivudine in pregnant chronic hepatitis B patientsChin J"/>
  <result pre="mutationsJ Viral Hepat20142180981724329944 22.ZhangLJWangLBlocking intrauterine infection by telbivudine in pregnant" exact="chronic hepatitis" post="B patientsChin J Hepatol200917561563 23.YangSLiuMWangLEffect of high viral hepatitis"/>
  <result pre="Viral Hepat20142180981724329944 22.ZhangLJWangLBlocking intrauterine infection by telbivudine in pregnant chronic" exact="hepatitis" post="B patientsChin J Hepatol200917561563 23.YangSLiuMWangLEffect of high viral hepatitis"/>
  <result pre="pregnant chronic hepatitis B patientsChin J Hepatol200917561563 23.YangSLiuMWangLEffect of high" exact="viral hepatitis" post="B virus DNA loads on vertical transmission of hepatitis"/>
  <result pre="chronic hepatitis B patientsChin J Hepatol200917561563 23.YangSLiuMWangLEffect of high viral" exact="hepatitis" post="B virus DNA loads on vertical transmission of hepatitis"/>
  <result pre="viral hepatitis B virus DNA loads on vertical transmission of" exact="hepatitis" post="B virus in late-pregnant womenZhonghua fu chan ke za"/>
  <result pre="NunenABNiestersHGde ManRASchalmSWJanssenHLLamivudine treatment during pregnancy to prevent perinatal transmission of" exact="hepatitis" post="B virus infectionJ Viral Hepat20031029429712823596 25.LiXMYangYBHouHYet al.Interruption of HBV"/>
  <result pre="pregnancy to prevent perinatal transmission of hepatitis B virus infectionJ" exact="Viral" post="Hepat20031029429712823596 25.LiXMYangYBHouHYet al.Interruption of HBV intrauterine transmission: a clinical"/>
  <result pre="28.LinYLiuYDingGet al.Efficacy of tenofovir in preventing perinatal transmission of HBV" exact="infection" post="in pregnant women with high viral loadsSci Rep201881551430341345 29.CelenMKMertDAyMet"/>
  <result pre="perinatal transmission of HBV infection in pregnant women with high" exact="viral" post="loadsSci Rep201881551430341345 29.CelenMKMertDAyMet al.Efficacy and safety of tenofovir disoproxil"/>
  <result pre="vertical transmission of HBV infectionWorld J Gastroenterol2013199377938224409065 30.ShenMLXuHTJuHFXianJCYangXZSequential telbivudine/lamivudine and" exact="hepatitis" post="B immunoglobulin therapy for preventing mother-to-infant transmission of hepatitis"/>
  <result pre="and hepatitis B immunoglobulin therapy for preventing mother-to-infant transmission of" exact="hepatitis" post="B virusWorld Chin J Digestol20162435173522 31.LiuJWangJYanTet al.Efficacy and safety"/>
  <result pre="and safety of telbivudine and tenofovir disoproxil fumarate in preventing" exact="hepatitis" post="B vertical transmission: a real-life practiceJ Viral Hepat2019261170117731177596 32.ZengJZhengCLiHEffectiveness"/>
  <result pre="fumarate in preventing hepatitis B vertical transmission: a real-life practiceJ" exact="Viral" post="Hepat2019261170117731177596 32.ZengJZhengCLiHEffectiveness of tenofovir or telbivudine in preventing HBV"/>
  <result pre="for pregnancyMedicine201998e1509230946367 33.ZhangBFChengMLZhangQet al.Clinical study on blocking mother-to-child transmission of" exact="hepatitis" post="B virus with high viral load and HBeAg positivity"/>
  <result pre="on blocking mother-to-child transmission of hepatitis B virus with high" exact="viral" post="load and HBeAg positivity during pregnancy in Guizhou ProvinceChin"/>
  <result pre="of telbivudine’s antiviral efficacy and protection against mother-to-infant transmission of" exact="chronic hepatitis" post="B during the first trimester of pregnancyChin J Hepatol201523912"/>
  <result pre="telbivudine’s antiviral efficacy and protection against mother-to-infant transmission of chronic" exact="hepatitis" post="B during the first trimester of pregnancyChin J Hepatol201523912"/>
  <result pre="safety of telbivudine in the treatment of childbearing patients with" exact="chronic hepatitis" post="BChin J Hepatol201422573576 36.HanGRJiangHXYueXet al.Efficacy and safety of telbivudine"/>
  <result pre="of telbivudine in the treatment of childbearing patients with chronic" exact="hepatitis" post="BChin J Hepatol201422573576 36.HanGRJiangHXYueXet al.Efficacy and safety of telbivudine"/>
  <result pre="in pregnant women for the prevention of perinatal transmission of" exact="hepatitis" post="B virus infectionJ Viral Hepat20152275476225641421 37.ChenZXGuGFBianZLet al.Clinical course and"/>
  <result pre="the prevention of perinatal transmission of hepatitis B virus infectionJ" exact="Viral" post="Hepat20152275476225641421 37.ChenZXGuGFBianZLet al.Clinical course and perinatal transmission of chronic"/>
  <result pre="infectionJ Viral Hepat20152275476225641421 37.ChenZXGuGFBianZLet al.Clinical course and perinatal transmission of" exact="chronic hepatitis" post="B during pregnancy: a real-world prospective cohort studyJ Infect20177514615428551372"/>
  <result pre="Viral Hepat20152275476225641421 37.ChenZXGuGFBianZLet al.Clinical course and perinatal transmission of chronic" exact="hepatitis" post="B during pregnancy: a real-world prospective cohort studyJ Infect20177514615428551372"/>
  <result pre="Infect20177514615428551372 38.ShengQDingYLiBet al.Efficacy and safety of nucleos(t)ide analogues to prevent" exact="hepatitis" post="B virus mother-to-child transmission in pregnant women with high"/>
  <result pre="pregnancy completely blocks HBV vertical transmissionBMC Gastroenterol2017175128407735 40.TanZYinYZhouJWuLXuCHouHTelbivudine treatment of" exact="hepatitis" post="B virus-infected pregnant women at different gestational stages for"/>
  <result pre="40.TanZYinYZhouJWuLXuCHouHTelbivudine treatment of hepatitis B virus-infected pregnant women at different" exact="gestational" post="stages for the prevention of mother-to-child transmission: outcomes of"/>
  <result pre="41.SunWMaLHaoAet al.Predictive value of telbivudine in preventing mother-to-infant transmission of" exact="hepatitis" post="B virus in pregnant women with high viremiaChin J"/>
  <result pre="43.DengYWuWZhangDet al.The safety of telbivudine in preventing mother-to-infant transmission of" exact="hepatitis" post="B virus in pregnant women after discontinuationChin J Hepatol201523586589"/>
  <result pre="after discontinuationChin J Hepatol201523586589 44.WuQHuangHSunXet al.Telbivudine prevents vertical transmission of" exact="hepatitis" post="B virus from women with high viral loads: a"/>
  <result pre="vertical transmission of hepatitis B virus from women with high" exact="viral" post="loads: a prospective long-term studyClin Gastroenterol Hepatol Off Clin"/>
  <result pre="Off Clin Pract J Am Gastroenterol Assoc20151311701176 45.PanCQLeeHMAntiviral therapy for" exact="chronic hepatitis" post="B in pregnancySemin Liver Dis20133313814623749670 46.HouJCuiFDingYet al.Management algorithm for"/>
  <result pre="Clin Pract J Am Gastroenterol Assoc20151311701176 45.PanCQLeeHMAntiviral therapy for chronic" exact="hepatitis" post="B in pregnancySemin Liver Dis20133313814623749670 46.HouJCuiFDingYet al.Management algorithm for"/>
  <result pre="Liver Dis20133313814623749670 46.HouJCuiFDingYet al.Management algorithm for interrupting mother-to-child transmission of" exact="hepatitis" post="B virusClin Gastroenterol Hepatol Off Clin Pract J Am"/>
  <result pre="safety of antiviral treatment on blocking the mother-to-child transmission of" exact="hepatitis" post="B virus: a meta-analysisJ Viral Hepat20192639740630417469"/>
  <result pre="blocking the mother-to-child transmission of hepatitis B virus: a meta-analysisJ" exact="Viral" post="Hepat20192639740630417469"/>
 </snippets>
</snippetsTree>
